相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
Philipp K. Haber et al.
GASTROENTEROLOGY (2021)
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
Michel Ducreux et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma
Jean-Louis Jouve et al.
JOURNAL OF HEPATOLOGY (2019)
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2019)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2019)
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
Philippe Merle et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
Ghassan K. Abou-Alfa et al.
JAMA ONCOLOGY (2019)
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Masaaki Kondo et al.
BMC CANCER (2019)
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
Joong-Won Park et al.
JOURNAL OF HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Masatoshi Kudo et al.
LIVER CANCER (2019)
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
G. K. Abou-Alfa et al.
ANNALS OF ONCOLOGY (2018)
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
D. H. Palmer et al.
BRITISH JOURNAL OF CANCER (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon- combination therapy for hepatocellular carcinoma with extrahepatic metastases
Hiroaki Nagano et al.
HEPATOLOGY RESEARCH (2018)
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
ONCOLOGY (2018)
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
Chia-Jui Yen et al.
LIVER CANCER (2018)
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Hamdy A. Azim et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2018)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valerie Vilgrain et al.
LANCET ONCOLOGY (2017)
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Tim Meyer et al.
LIVER INTERNATIONAL (2017)
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
Masatoshi Kudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
M. Ikeda et al.
ANNALS OF ONCOLOGY (2016)
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Ann-Lii Cheng et al.
HEPATOLOGY (2016)
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2015)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2015)
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
Bruno Vincenzi et al.
PLOS ONE (2015)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
分享论文
